Adventrx Pharmaceuticals, Inc.
6725 Mesa Ridge Road
Suite 100
San Diego,
CA 92121
United States - Map
Phone: 858-552-0866
Fax: 858-552-0876
Web Site: http://www.adventrx.com
| ADVENTRX Pharmaceuticals, Inc., a biopharmaceutical company, focuses on in-licensing, developing, and commercializing proprietary product candidates for the treatment of cancer. Its lead product candidates include ANX-530, a novel emulsion formulation of chemotherapy drug vinorelbine to treat advanced non-small cell lung cancer as a single agent or in combination with cisplatin, as well as to treat advanced or metastatic breast cancer; and ANX-514, a novel emulsion formulation of the chemotherapy drug docetaxel for the treatment of breast, non-small cell lung, prostate, gastric, and head and neck cancers. The company was founded in 1995 is based in San Diego, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Brian M. Culley M.S., M.B.A., 37
Principal Exec. Officer, Chief Bus. Officer and Sr. VP of Bus. Devel. |
N/A
| N/A | Mr. Patrick L. Keran J.D., 37
Interim Principal Financial Officer, Interim Principal Accounting Officer, VP of Legal, Sec. and Gen. Counsel |
$
231.00K | N/A | Mr. Mark N.K. Bagnall C.P.A., 52
Consultant |
$
272.00K | N/A | Mr. Mark E. Erwin , 44
Sr. VP of Operations |
N/A
| N/A | Ms. Michele L. Yelmene , 45
VP of Regulatory Affairs |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.29% Nasdaq 
Profile
